Biosimilar Interleukins Market Trends 2025-2034: Growth, Strategic Insights, and Opportunities Ahead
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
Which Primary Drivers Are Supporting the Continued Market Growth of theBiosimilar Interleukins Market?
The rising prevalence of autoimmune diseases like psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market. These diseases cause the immune system to attack healthy cells, and anti-interleukin biologic drugs have shown significant clinical benefits. According to the NIH in February 2024, the global incidence and prevalence of autoimmune diseases are increasing annually, driving the demand for interleukin biosimilars.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp
#How Will the CAGR of the Biosimilar Interleukins Market Influence Its Overall Growth by 2034?
The biosimilar interleukins market size has grown exponentially in recent years. It will grow from $3.9 billion in 2024 to $5.41 billion in 2025 at a compound annual growth rate (CAGR) of 39.0%. The growth is driven by the increasing prevalence of autoimmune diseases, government support for biosimilars, growing patient demand, and the expanding availability of biosimilars in the market.
The biosimilar interleukins market is expected to grow rapidly, reaching $20.79 billion by 2029 at a CAGR of 40.0%. The market’s expansion can be attributed to a growing patient population, increased healthcare access, rising demand for personalized medicine, and the shift toward minimally invasive procedures. Notable trends during the forecast period include advancements in biosimilar technology, targeted immunotherapies, quality control in manufacturing, and global collaboration.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3433
What Are the Most Significant Market Trends Transforming theBiosimilar Interleukins Market?
In the biosimilar interleukins market, major firms are launching new products such as Tofidence (tocilizumab-bavi) to bolster profitability. Tofidence is a monoclonal antibody that binds to interleukin-6 receptors and is used to treat inflammatory autoimmune diseases. In September 2023, Biogen, a biotechnology company based in the U.S., received FDA approval for Tofidence, the first biosimilar to Genentech’s Actemra (tocilizumab). Administered via intravenous infusion, Tofidence is approved to treat active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
Who Are the Key Market Players Influencing the Growth of the Corn and Biosimilar Interleukins Industry?
Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.
https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report
Which Key Market Segments Comprise the Biosimilar Interleukins Market and Drive Its Revenue Growth?
The biosimilar interleukins market covered in this report is segmented –
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes
Subsegments:
1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management
2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment
3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders
4) By IL-5: Asthma Treatment, Eosinophilic Disorders
5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=3433&type=smp
Which Regions Are Emerging as Leaders in the Biosimilar Interleukins Market?
The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Browse Through More Reports Similar to the Global Biosimilar Interleukins Market 2025, By The Business Research Company:
Oncology Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report
Pegfilgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID 19 Impact And Recovery
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-market
Biosimilar Therapeutic Peptides Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
